Ticagrelor for preventing atherothrombotic events after myocardial infarction
KEYWORDS: ticagrelor, committee, treatment, myocardial, infarction, myocardial infarction, risk, company, clinical, atherothrombotic, patients, therapy, aspirin, considered, events

the myocardial infarction, or within 1 year after stopping previous ADP receptor inhibitor treatment. Unless contraindicated, ticagrelor should always be given with a daily low maintenance dose of aspirin 75 mg to 150 mg. There are limited data on the efficacy and safety of ticagrelor beyond 3 years of extended treatment. Ticagrelor costs Â£54.60 for a 56-tablet pack (28 days' supply). Costs may Price vary in different settings because of negotiated procurement discounts. 3 Evidence The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group. See the committee papers for full details of the evidence. 4 Committee discussion The appraisal committee reviewed the data available on the clinical and cost effectiveness of extended therapy with ticagrelor 60 mg twice daily plus aspirin (hereafter referred to as ticagrelor), having considered evidence on the nature of preventing atherothrombotic events in people with a history of myocardial infarction and at high risk of atherothrombotic events, and the value placed on the benefits of ticagrelor by people with the condition, those who represent them, and clinical experts. It also took into account the effective use of NHS resources. Nature of the treatment and patient perspective
